Key result
Dyslipidemia alone shows no link to trastuzumab-induced cardiotoxicity in breast cancer patients.
Why the study?
Breast cancer patients undergoing trastuzumab therapy have greater risk of cardiovascular disease, but the role of dyslipidemia in trastuzumab-induced cardiotoxicity is not completely understood.
Does dyslipidemia increase the risk of trastuzumab-induced cardiotoxicity in breast cancer patients?
Systematic Review
Does dyslipidemia increase the risk of trastuzumab-induced cardiotoxicity in breast cancer patients?
Dyslipidemia alone is not significantly associated with trastuzumab-induced cardiotoxicity, suggesting that in the absence of other risk factors, routine cardio-oncology referral solely for dyslipidemia may not be necessary.
Answers are grounded in this paper and cite their sources.
May not warrant routine cardio-oncology referral for isolated dyslipidemia; leaves open effects with additional risk factors.
INTRODUCTION: Breast cancer patients undergoing trastuzumab therapy have greater risk of cardiovascular disease. Risk factors for this effect have been proposed. However, the role of dyslipidemia is not completely understood. This systematic review aimed to explore the role of dyslipidemia in trastuzumab-induced cardiotoxicity. METHODS: The investigators searched MEDLINE, Scopus, and Web of Science up to October 25, 2020. A random-effects model was used to determine pooled estimates of the results. The primary endpoint was trastuzumab-induced cardiotoxicity in patients with and without dyslipidemia. CONCLUSION: This systematic review and meta-analysis did not demonstrate a significant association between dyslipidemia alone and the development of cardiotoxicity. In the absence of other relevant cardiovascular risk factors, review of lipid profile may not be obligatory, and management of patients could be performed without referral for cardio-oncology assessment. Further investigation of risk factors for trastuzumab-induced cardiotoxicity is required to confirm these results.
No takes yet. Share an insight, caveat, or question.
Pinho et al. (2023) conducted a systematic review in Breast cancer. Dyslipidemia vs. Without dyslipidemia was evaluated on Trastuzumab-induced cardiotoxicity. Dyslipidemia alone was not significantly associated with the development of trastuzumab-induced cardiotoxicity in breast cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: